.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Johnson and Johnson
UBS
Accenture
Express Scripts
Teva
Cerilliant
Argus Health
Cantor Fitzgerald
Boehringer Ingelheim

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,673,939

« Back to Dashboard

Which drugs does patent 8,673,939 protect, and when does it expire?


Patent 8,673,939 protects POMALYST and is included in one NDA. There has been one Paragraph IV challenge on Pomalyst.

This patent has two hundred and seventy-three patent family members in thirty-six countries.

Summary for Patent: 8,673,939

Title:Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Inventor(s): Zeldis; Jerome B. (Princeton, NJ)
Assignee: Celgene Corporation (Summit, NJ)
Application Number:13/782,728
Patent Claim Types:
see list of patent claims
Use; Delivery; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
CelgenePOMALYSTpomalidomideCAPSULE;ORAL204026-001Feb 8, 2013RXYesNo► Subscribe► Subscribe► SubscribeUSE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
CelgenePOMALYSTpomalidomideCAPSULE;ORAL204026-002Feb 8, 2013RXYesNo► Subscribe► Subscribe► SubscribeUSE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
CelgenePOMALYSTpomalidomideCAPSULE;ORAL204026-003Feb 8, 2013RXYesNo► Subscribe► Subscribe► SubscribeUSE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
CelgenePOMALYSTpomalidomideCAPSULE;ORAL204026-004Feb 8, 2013RXYesYes► Subscribe► Subscribe► SubscribeUSE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,673,939

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,440,194Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias► Subscribe
8,410,136Methods for treatment of hepatocellular carcinoma using 3-(4-amino-1-OXO-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione► Subscribe
7,968,569Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione► Subscribe
8,530,498Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione► Subscribe
9,283,215Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione in combination with antibodies► Subscribe
9,353,080Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione► Subscribe
8,207,200Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroindol-2-yl)-piperidine-2,6-dione follow by autologous stem cell transplantation► Subscribe
9,155,730Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent► Subscribe
9,101,622Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone► Subscribe
8,193,219Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,673,939

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan2009173683► Subscribe
Japan2013049734► Subscribe
Japan5830005► Subscribe
European Patent Office1567158► Subscribe
European Patent Office1635826► Subscribe
European Patent Office1667682► Subscribe
European Patent Office1931343► Subscribe
European Patent Office2087891► Subscribe
European Patent Office2105135► Subscribe1590004-6Sweden► Subscribe
European Patent Office2105135► SubscribeC300717Netherlands► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Chinese Patent Office
Argus Health
Mallinckrodt
Dow
US Department of Justice
Healthtrust
Moodys
Covington
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot